Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Cost is king when it comes to staying on GLP-1s. A real-world study found that out-of-pocket spending — not just side effects — is one of the biggest drivers of GLP-1 discontinuation. With 4 in 10 obesity patients paying cash and fewer than 1 in 5 employers covering these drugs for weight loss, access remains deeply unequal.
GLP-1 receptor agonists can deliver impressive, sustained weight loss — but only if patients can afford to keep taking them. A real-world analysis using data from the Understanding America Study (UAS) found that cost is one of the strongest predictors of whether patients stick with GLP-1 therapy, rivaling or even outpacing side effects as a reason for stopping.
The study surveyed U.S. adults between October and December 2025, finding that 13.7% had used a GLP-1, with nearly half using it primarily for weight loss. Among those patients, 43% had no insurance coverage for the drug — and about 4 in 10 were paying entirely out of pocket.
By the Numbers:
Why it matters: These findings highlight a growing equity gap in GLP-1 access. Expanding insurance coverage and reducing out-of-pocket costs may be the most direct policy lever to ensure the patients who need these drugs most are actually able to benefit from them long-term.